Capsule Sponge + Biomarkers Can Stratify Risk in Barrett Esophagus
By Elana Gotkine HealthDay Reporter
MONDAY, June 30, 2025 -- In adult patients with nondysplastic Barrett esophagus at last endoscopy, a subsequent capsule-sponge test can assist in identifying those at highest risk of dysplasia or cancer, according to a study published online June 23 in The Lancet.
W. Keith Tan, M.B.Ch.B., from Cambridge University in the United Kingdom, and colleagues prospectively evaluated a prespecified risk stratification tool -- comprising a pan-esophageal cell collection device coupled with biomarkers -- to establish whether it can identify those at highest risk of dysplasia or cancer. Adult patients with nondysplastic Barrett esophagus at their last endoscopy had a capsule-sponge test and were assigned as low, moderate, or high risk.
A total of 910 patients were recruited, 15, 31, and 54 percent were classified as high, moderate, and low risk, respectively. The researchers found that in the high-risk group, the positive predictive value for any dysplasia or worse was 37.7 percent. The highest risk of high-grade dysplasia or cancer was seen for patients with both atypia and aberrant p53 (relative risk, 135.8 relative to the low-risk group). In the low-risk group, the prevalence of high-grade dysplasia or cancer was 0.4 percent; the negative predictive value was 97.8 percent for any dysplasia or cancer. The proportion needing p53 pathology review could be reduced to 32 percent, without missing any positive cases, by applying a machine learning algorithm as part of a digital pathology workflow.
"The capsule sponge can be administered easily and quickly by nurses with only limited training required and will not need to take up precious endoscopy resources," Tan said in a statement.
Several authors who are named on patents related to this test disclosed ties to Cyted Health and Medtronic. Medtronic holds the license for the cytosponge technology.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2025
Read this next
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
FRIDAY, June 27, 2025 -- For patients with locally advanced head and neck squamous cell carcinoma (HNSCC), the addition of neoadjuvant and adjuvant pembrolizumab to standard care...
Telehealth Intervention Beneficial for Seniors With Metastatic Cancer
WEDNESDAY, June 25, 2025 -- The telehealth-administered Geriatric Assessment–Guided Intervention (GAIN-S) improves physical function, mood, quality of life, and prognostic...
Incidence Rates of Appendiceal Adenocarcinoma Increasing
MONDAY, June 16, 2025 -- The incidence rates of appendiceal adenocarcinoma (AA) increased after 1945, according to a study published online June 10 in the Annals of Internal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.